Gut Bacteria Metabolite Reduces Atherosclerosis in Mice

Researchers have identified a specific gut microbial metabolite that can alleviate atherosclerosis in mice, according to a study published online on October 7, 2026, in the journal Nature. The administration of the bacterium *Bacteroides uniformis* to mice was shown to mitigate atherosclerosis, a condition characterized by the buildup of plaques in arteries. This beneficial effect is attributed to a metabolite produced by the bacterium, identified as pentadecanoic acid. Pentadecanoic acid acts directly on a key enzyme in cholesterol metabolism, HMG-CoA reductase. By inhibiting this enzyme, pentadecanoic acid promotes the clearance of cholesterol from the liver, which in turn helps to reduce the progression of atherosclerotic plaques.

Atherosclerosis is a significant contributor to cardiovascular diseases, including heart attacks and strokes, and is a leading cause of death globally. The development of atherosclerosis is a complex process involving inflammation, lipid accumulation, and the formation of arterial plaques. Current treatments often focus on lifestyle modifications, statin medications that inhibit HMG-CoA reductase, and surgical interventions. The discovery of a naturally occurring compound from the gut microbiome that can directly influence cholesterol metabolism offers a novel therapeutic avenue.

The study highlights the intricate relationship between the gut microbiome and host health. The gut microbiome, comprising trillions of microorganisms, plays a crucial role in various physiological processes, including digestion, immune system development, and even brain function. Dysbiosis, an imbalance in the gut microbial community, has been linked to a wide range of diseases, including metabolic disorders, inflammatory conditions, and cardiovascular diseases. This research adds to the growing body of evidence suggesting that targeting the gut microbiome could be a powerful strategy for disease prevention and treatment.

The mechanism by which pentadecanoic acid exerts its effects involves the direct inhibition of HMG-CoA reductase. This enzyme is a critical component of the mevalonate pathway, which is responsible for the synthesis of cholesterol in the liver. Statins, a widely prescribed class of drugs for lowering cholesterol, also target HMG-CoA reductase. However, pentadecanoic acid represents a naturally derived compound that achieves a similar outcome. The subsequent promotion of hepatic cholesterol clearance suggests that the liver becomes more efficient at removing excess cholesterol from the bloodstream, thereby reducing its deposition in the arterial walls. This finding opens possibilities for developing new dietary interventions or probiotic therapies aimed at increasing the levels of beneficial metabolites like pentadecanoic acid in individuals at risk of or suffering from atherosclerosis.